medigraphic.com

2009, Number 4

<< Back Next >>

Rev Fac Med UNAM 2009; 52 (4)

Fulminant purpura due to Staphylococcus aureus

González IFP, Hernández IC, Millán MA, Ochoa HLA, Ibarra MJJ, Nieto VA

Language: Spanish
References: 20
Page: 156-160
PDF size: 231.30 Kb.


ABSTRACT

Background: Purpura fulminans is an acute illness commonly associated with meningococcemia or invasive streptococcal disease. It is characterized by disseminated intravascular coagulation and purpuric skin lesions. In this article we report a case of purpura fulminans associated with Staphylococcus aureus. Methods: The case was identified in the General Hospital of Mazatlán, Sinaloa, México during 2007. Staphylococcus aureus infection was diagnosed on the basis of culture result. Susceptibility to methicillin was determined. The ability of the isolated organism to produce superantigens was not possible to determine. Results: The isolated strain of Staphylococcus aureus in the present case was isolated from secretion of a non damaged flictena; the organism was not obtained from blood cultures. The isolated strain was methicillin resistant. We used immunomodulator drugs as alfa-2a interferon and thalidomide, antibiotics and support measures. The patient survived with complete extremities. Conclusions: Purpura fulminans due to Staphylococcus aureus is a newly and emerging disease commonly associated with superantigen production. It is a very aggressive and even fatal illness that deserves special attention.


REFERENCES

  1. Kravitz G, Dries D, Peterson M, Schlievert P. Purpura fulminans due to Staphylococcus aureus. Clinical Infectious Diseases 2005; 40: 941-947.

  2. Harrison OB, Robertson BD, Faust SN et al. Analysis of pathogen host cell interactions in purpura fulminans: expression of capsule, type IV pili, and PorA by Neisseria meningitidis in vivo. Infect Immun 2002; 70: 5193-201.

  3. Centers for Disease Control and Prevention. Summary of notifiable diseases, United States, 1998. MMWR Morb Mortal Wkly Rep 1999;.

  4. Wenzel RP, Edmond MB. The impact of hospital-acquired bloodstream infections. Emerg Infect Dis 2001; 7: 174-7.

  5. Robboy SJ, Mihm MC, Colman RW, Minna JD. The skin in disseminated intravascular coagulation: prospective analysis of thirty-six cases. Br J Dermatol 1973; 88: 221-9.

  6. Rintala E, Kauppila M, Seppala OP et al. Protein C substitution in sepsis-associated purpura fulminans. Crit Care Med 2000; 28: 2373-8.

  7. Murray HW, Tuazon CU, Sheagren JN. Staphylococcal septicemia and disseminated intravascular coagulation: Staphylococcus aureus endocarditis mimicking meningococcemia. Arch Intern Med 1977; 137: 844-7.

  8. Willcox PA, Rayner BL, Whitelaw DA. Community-acquired Staphylococcus aureus bacteriemia in patients who do not abuse intravenous drugs. QJM 1998; 91: 41-7.

  9. McCormick JK, Yarwood JM, Schlievert PM. Toxic shock syndrome and bacterial superantigens: an update. Annu Rev Microbiol 2001; 55: 77-104.

  10. Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives. Science 1990; 248: 705-11.

  11. Kotzin BL, Leung DY, Kappler J, Marrack P. Superantigens and their potential role in human disease. Adv Immunol 1993; 54: 99-166.

  12. Schlievert PM, Tripp TJ, Peterson ML. Reemergence of staphylococcal toxic shock syndrome in Minneapolis-St. Paul, Minnesota, during the 2000-2003 surveillance period. J Clin Microbiol 2004; 42: 2875-6.

  13. Hamza MH. Treatment of Behçet’s disease with thalidomide. Clin Rheumatol 1986; 5: 365-71.

  14. Cattelan AM, Trevenzoli M, Aversa SM. Recent advances in the treatment of AIDS-related Kaposi’s sarcoma. Am J Clin Dermatol 2002; 3: 451-62.

  15. Pandit S, Vesole DH. Relapsed multiple myeloma. Curr Treat Optiosn Oncol 2001; 2: 261-9.

  16. Zorat F, Pozzato G. Thalidomide in myelodisplastic syndromes. Biomed Pharmacother 2002; 56: 20-30.

  17. Krown SE. Management of Kaposi sarcoma: the role of interpheron and thalidomide. Curr Opin Oncol 2001; 13: 374-81.

  18. Levin M, Eley BS, Louis J, Cohen H, Young L, Heyderman RS. Postinfectious purpura fulminans caused by an autoantibody directed against protein S. J Pediatr 1995; 127: 355-63.

  19. Gampar G, Oschazt E, Herkner H et al. Sepsis-associated purpura fulminans in adults. Wien Klin Woehenschr 2001; 113: 107-12.

  20. Nolan J, Sinclair R. Review of management of purpura fulminans and two case reports. Br J Anaesth 2001; 86: 581-6.




2020     |     www.medigraphic.com